Compare Atomera Incorporated (ATOM) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atomera Incorporated vs Charles River Laboratories Intl. Inc — how do they compare? Atomera Incorporated trades at $6.48 (market cap $247.40M), while Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 45× Atomera Incorporated's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Atomera Incorporated nearer its low. Which is the better fit depends on your goals.
| ATOM | CRL | |
|---|---|---|
Market Cap | $247.40M | $11.14B |
Sector | Technology | Health |
52-Week High | $12.11 | $233.60 |
52-Week Low | $1.99 | $145.57 |
Enterprise Value | $207.61M | $14.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ATOM trades at $6.25, down 5.73% over 24 hours, reflecting a bearish technical outlook with negative earnings trends. The company reported a net loss of $20.17 million in 2025 on minimal revenue of $65,000, with profitability metrics deeply negative. Recent news highlights Atomera's focus on semiconductor technology advancements, including GaN-on-Silicon collaborations, but financial performance remains a significant concern.
The outlook is cautious due to persistent losses and weak revenue, though analyst consensus is unanimously bullish with a 100% buy rating. Key risks include execution challenges in monetizing technology and high cash burn. Upside depends on successful commercialization of its semiconductor IP, but current fundamentals suggest high volatility and substantial shareholder risk.
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atomera Incorporated
Atomera is a semiconductor materials engineering company. Its Mears Silicon Technology (MST) is a patented thin film that enhances transistor performance, power efficiency, and cost for global chip manufacturers.
Read more on ATOM →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
